SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-013523
Filing Date
2022-05-16
Accepted
2022-05-16 08:05:47
Documents
62
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1361245
2 ex31-1.htm EX-31.1 11678
3 ex31-2.htm EX-31.2 11749
4 ex32-1.htm EX-32.1 5925
5 ex32-2.htm EX-32.2 6208
  Complete submission text file 0001493152-22-013523.txt   4660395

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avte-20220331.xsd EX-101.SCH 29317
7 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT avte-20220331_cal.xml EX-101.CAL 51527
8 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avte-20220331_def.xml EX-101.DEF 109927
9 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avte-20220331_lab.xml EX-101.LAB 279865
10 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avte-20220331_pre.xml EX-101.PRE 221475
56 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 540068
Mailing Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116
Business Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

IRS No.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40544 | Film No.: 22925617
SIC: 2834 Pharmaceutical Preparations